Introduction of the Department
The Department of Hematology of the Children’s Hospital, founded in 2007, is the only specialized pediatric hematological department within the province. It owns an outstanding and professional team as well as complete pediatric hematological labs and testing apparatuses. Every year, it receives and treats highest number of patients of pediatric hematological diseases within Xinjiang, and the treated diseases cover all almost all the pediatric hematological diseases.
There are altogether 7 physicians, 2 docimasters and 14 nurses. The department sets up 30 beds, blood lab (equipped with relatively advanced BD flow cytometry and bone marrow imaging analyzer), and pediatric homological specialist outpatient service.

The range of treatment covers all the pediatric hematological diseases, including pediatric acute/chronic leukemia, hemophagocytic syndrome, Langerhans cell histiocytosis, lymphoma, aplastic anemia, immune hemolytic anemia, thalassemia, immune thrombopenia, hemophilia, other blood coagulation factor-deficient or alimentary anemia, Gaucher’s disease, and Nieman-Pick syndrome.












Introduction to the Experts


Name: Wang Shuhong
Job title: Chief Physician
Specialty: diagnosis and treatment of pediatric hematological diseases, such as pediatric leukemia, hemorrhage and blood coagulation disorder, hemophagocytic syndrome, lymphoma, aplastic anemia, immune hemolytic anemia, and immune thrombopenia with nearly 20 years’ working experience.


Advanced instrument
Flow cytometry (FCM) (BD FACSCalibur)
It can be applied to the cell phenotype analysis as well as detection of minimal residual leukemia, T cell subset, HLA-B27 and NBT.




Advanced instrument
The 3-year-old patient was admitted with the chief complaint about “having fever and pale complexion for 4 days”.
After the admission, detailed marrow cytology examination revealed 63.5% of primary +juvenile lymphocytes. The patient was definitely diagnosed as having acute lymphoblastic leukemia and was further determined as acute B-type lymphoblastic leukemia according to immunophenotyping without abnormal fused gene or chromosome. The patient was preliminarily graded as standard risky. Prednisone was prescribed in accordance with CCLG-2008 chemotherapeutic plan. On the 7th day of prednisone therapy, no juvenile cell was seen in peripheral blood. Routine bone marrow examination revealed local blood dilution and visible juvenile lymphocyte of about 13.5% with partly dissolution on the 15th day of treatment, bone marrow smear revealed active bone marrow proliferation, juvenile lymphocyte accounting for 6.5%, and residual leukemic cell (MRD) <10-4 on the 33rd day. The chemotherapy was continued at standard risky level. Now the patient was already in the maintenance treatment and the MRD in regular examination is below 10-4.










The 3-year-old patient was admitted after being discovered to have “enclosed mass in right temporal bone for one month”. With further cranial biopsy and immunohistochemical examination in the lesion, the patient was diagnosed as having Langerhans cell histiocytosis (Letterer-Siwe). The disease was a set of Langerhans cell pathological proliferating diseases of unknown causes, which could involve multiple organs such as skeleton, skin, ear, lymph gland, oral cavity, lung, liver, spleen, bone marrow, and central nervous system.
After being hospitalized, the patient accepted detailed auxiliary examinations and was found to have such organs involved as skeleton (skull, bilateral humerus, and eighth dorsal vertebra), and liver. The liver was at peril. LCH-III-Group-I chemotherapy was administered for 42 weeks, and the process was very smooth. After that, the patient’s condition was improved.
The patient was the first case of Langerhans cell histiocytosis diagnosed and treated by our hospital. Now we keep paying follow up to the patient, and find the patient is in good conditions.